𝔖 Bobbio Scriptorium

✦ LIBER ✦

Cetuximab in advanced non-small-cell lung cancer (NSCLC)

✍ Scribed by Pirker, Robert

Book ID: 119320842
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 58 KB
Volume: 77
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.05.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN97 ADVANCED NON-SMALL CELL LUNG CANCE

PCN97 ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) CETUXIMAB TREATMENT DECISION MODEL: CHEMOTHERAPY+CETUXIMAB VS. CETUXIMAB TREAT-TO-RASH STRATEGY VS. CHEMOTHERAPY ONLY IN FIRST-LINE TREATMENT OF STAGE IIIB/IV NSCLC

✍ J Roth; J Carlson 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

Docetaxel–carboplatin chemotherapy combi

Docetaxel–carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)—Results of the nonrandomised phase II study TaxErb

✍ Fischer, J.R.; Griesinger, F.; Fink, T.; Salm, T.; Marseille, A.; Wolf, M. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 271 KB

PCN41 COST-SAVINGS ASSOCIATED WITH BEVAC

PCN41 COST-SAVINGS ASSOCIATED WITH BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

✍ D Heigener; HG Bischoff; C Wiesner; R Aultman 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

55 Randomized phase II clinical trial of

55 Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC)

✍ R. Rosell; R. Ramlau; A. Szczesna; C. Daniel; M. Bertrand; R. Garcia-Arroyo; K. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

PCN47 COSTS OF TREATING SEVERE ADVERSE E

PCN47 COSTS OF TREATING SEVERE ADVERSE EVENTS OBSERVED WITH A REGIMEN OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

✍ HG Bischoff; D Heigener; K Banz; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

PCN44 TREATMENT COSTS OF GRADE 3/4 ADVER

PCN44 TREATMENT COSTS OF GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ J de Castro Carpeño; K Banz; AJ Castro 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB